Carregant...
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
Anifrolumab (anifrolumab) is an antagonist human monoclonal antibody that targets interferon α receptor 1 (IFNAR1). Anifrolumab has been developed to treat autoimmune diseases and is currently in clinical trials. To decipher the molecular basis of its mechanism of action, we engaged in multiple epit...
Guardat en:
| Publicat a: | MAbs |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622752/ https://ncbi.nlm.nih.gov/pubmed/25606664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1007810 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|